Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System

Sherif, Abdelrahman Y.; Harisa, Gamaleldin I.; Alanazi, Fars K.; Youssof, Abdullah M. E.

doi:10.2174/1389450120666190715104100

Cited by 21 publications

(18 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it could be concluded that GEF-P-NLC produces cytotoxic activity through the aforementioned mechanism. This not only increases the efficacy of therapeutic outcomes but also decreases the toxicity of GEF by decreasing the required dose [49]. Taken all together, TPGS engineered nanoscale lipid-based LDDS is expected to increase the therapeutic outcomes of GEF during the treatment of metastatic lung cancer.…”

Section: Apoptotic Studymentioning

confidence: 98%

Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line

et al. 2022

Self Cite

View full text Add to dashboard Cite

The present study aimed to engineer a nanoscale lipid-based lymphatic drug delivery system with D-α-Tocopherol polyethylene glycol 1000 succinate to combat the lymphatic metastasis of lung cancer. The nanoscale lipid-based systems including GEF-SLN, GEF-NLC, and GEF-LE were prepared and pharmaceutically characterized. In addition, the most stable formulation (GEF-NLC) was subjected to an in vitro release study. Afterward, the optimized GEF-NLC was engineered with TPGS (GEF-TPGS-NLC) and subjected to in vitro cytotoxicity, and apoptotic studies using the A549 cells line as a surrogate model for lung cancer. The present results revealed that particle size and polydispersity index of freshly prepared formulations were ranging from 198 to 280 nm and 0.106 to 0.240, respectively, with negative zeta potential ranging from − 14 to − 27.6.mV. An in vitro release study showed that sustained drug release was attained from GEF-NLC containing a high concentration of lipid. In addition, GEF-NLC and GEF-TPGS-NLC showed remarkable entrapment efficiency above 89% and exhibited sustained release profiles. Cytotoxicity showed that IC 50 of pure GEF was 11.15 μg/ml which decreased to 7.05 μg/ml for GEF-TPGS-NLC. The apoptotic study revealed that GEF-TPGS-NLC significantly decreased the number of living cells from 67 to 58% when compared with pure GEF. The present results revealed that the nanoscale and lipid composition of the fabricated SLN, NLC, and LE could mediate the lymphatic uptake of GEF to combat the lymphatic tumor metastasis. Particularly, GEF-TPGS-NLC is a promising LDDS to increase the therapeutic outcomes of GEF during the treatment of metastatic lung cancer.

show abstract

Section: Apoptotic Studymentioning

confidence: 98%

Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The advantage is that RBCs can effectively target the reticuloendothelial system. And the release of the drug and the maintenance of the plasma drug concentration can be controlled ( Sherif et al, 2019 ). However, cells as drug transport carriers still face many problems, such as uncertain cell differentiation, cell embolism, infection, and difficulties in production and storage.…”

Section: Production Process Of Exosomesmentioning

confidence: 99%

The status of industrialization and development of exosomes as a drug delivery system: A review

Yin

Han

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Exosomes, as natural biomolecular carriers produced by cells, have the potential and advantage of delivering drugs to target organs or cells in vivo. The steps to improve exosomes as a drug delivery system can be divided into three steps:large-scale preparation of exosomes, loading of drugs and targeted delivery of exosomes. Based on the existing production process and technology, there is still much room for improvement. This review highlights the research progress in three aspects and proposes new technologies and innovative approaches to improve the efficiency of exosome delivery.

show abstract

“…For efficient drug delivery, drugs can firstly be ingested into cell. Then, these drugs will be load into sEVs with the formation process of sEVs [ 128 ]. Ingesting specific drug can sometimes stimulate donor cells to produce other therapeutic substances which will be packed into sEVs [ 84 , 86 ].…”

Section: Applications Of Modulated Sevs In Disease Treatmentsmentioning

confidence: 99%

Regulating the production and biological function of small extracellular vesicles: current strategies, applications and prospects

Luo

Wang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Numerous studies have confirmed the great application potentials of small extracellular vesicles (sEVs) in biological medical field, especially in tissue repair and regeneration. However, the production capability of sEVs by noncancerous cells is very limited, while their dosage requirements in disease treatments are usually very high. Meanwhile, as cell aging, the sEV production capability of cells decreases and the biological function of sEVs changes accordingly. In addition, for special applications, sEVs carrying desired bioactive substances should be designed to perform their expected biological function. Therefore, improving the production of sEVs and precisely regulating their biological function are of great significance for promoting the clinical applications of sEVs. In this review, some of the current classic strategies in affecting the cellular behaviors of donor cells and subsequently regulating the production and biological function of their sEVs are summarized, including gene engineering methods, stress-inducing conditions, chemical regulators, physical methods, and biomaterial stimulations. Through applying these strategies, increased yield of sEVs with required biological function can be obtained for disease treatment and tissue repair, such as bone regeneration, wound healing, nerve function recovery and cancer treatment, which could not only reduce the harvest cost of sEV but promote the practical applications of sEVs in clinic. Graphical Abstract

show abstract

Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System

Cited by 21 publications

References 108 publications

Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line

Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line

The status of industrialization and development of exosomes as a drug delivery system: A review

Regulating the production and biological function of small extracellular vesicles: current strategies, applications and prospects

Contact Info

Product

Resources

About